BioSpace News Archive

Michele F. Loscocco is new leader of prominent Mid-Atlantic medical physics consulting company.

Study Published in Scientific Reports Demonstrates Prevention of Inflammation in a Cardiovascular Disease Model

Solasia Pharma K.K. announced that patient registration reached the target number of cases for the darinaparsin Phase 2 study.

Bayer to lead $40M Series B financing and license One Drop’s digital platform and leverage its A.I. capabilities globally in other therapeutic areas; Stefan Oelrich, Head of Bayer Pharmaceuticals, to join One Drop’s Board of Directors

SciBite, the award-winning semantic technology company, last week hosted its annual US-based customer meeting at Novartis Institutes for BioMedical Research in Boston, MA, sparking ‘clean data’ discussions.

ArQule, Inc. announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on Tuesday, September 24, 2019 at The Parker New York Hotel in New York City.

Encoded Therapeutics, Inc. (Encoded), a precision gene therapy company, today announced a significant expansion of its leadership team, strengthening its capabilities in corporate development and gene therapy manufacturing.

DURECT Corporation (Nasdaq: DRRX) today announced that it has completed the Phase 2a clinical trial of its lead product candidate, DUR-928, in patients with alcoholic hepatitis (AH).

UC’s U.S. CRISPR-Cas9 portfolio is most comprehensive for the gene-editing technology

Luminaries from industry, healthcare and academia are converging at the Leadership in the Age of Personalization® Executive Summit, on October 9, 2019 in Huntington Beach, California, presented by GLLG.